Intensity Therapeutics, Inc.
INTS
$0.282
-$0.009-3.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.71% | -37.50% | -20.31% | 24.58% | 316.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.64% | -28.44% | -4.45% | 43.32% | 315.15% |
| Operating Income | 46.64% | 28.44% | 4.45% | -43.32% | -315.15% |
| Income Before Tax | 48.96% | 27.29% | -0.28% | -50.84% | -34.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.96% | 27.29% | -0.28% | -50.84% | -34.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.96% | 27.29% | -0.28% | -50.84% | -34.32% |
| EBIT | 46.64% | 28.44% | 4.45% | -43.32% | -315.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 62.90% | 34.31% | 4.12% | -49.27% | 74.63% |
| Normalized Basic EPS | 62.93% | 34.27% | 4.10% | -49.16% | 11.42% |
| EPS Diluted | 62.90% | 34.31% | -91.84% | -49.27% | 74.63% |
| Normalized Diluted EPS | 62.93% | 34.27% | 4.10% | -49.16% | 11.42% |
| Average Basic Shares Outstanding | 37.60% | 10.68% | 4.62% | 1.05% | 289.93% |
| Average Diluted Shares Outstanding | 37.60% | 10.68% | 4.62% | 1.05% | 289.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |